Evidence was obtained that arming MV with GM-CSF improves the attraction of immune cells to a tumor and enhances the induction of a tumor-specific immune response.156 It is highly likely that the encouraging results obtained using the murine model can be translated into successful clinical trials benefiting cancer patients. The gene discussed is CSF2; the disease is cancer.